Your browser is no longer supported. Please, upgrade your browser.
DNLI Denali Therapeutics Inc. daily Stock Chart
DNLI [NASD]
Denali Therapeutics Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own3.60% Shs Outstand102.42M Perf Week1.89%
Market Cap2.72B Forward P/E- EPS next Y-2.56 Insider Trans-64.09% Shs Float97.78M Perf Month0.78%
Income-215.40M PEG- EPS next Q-0.60 Inst Own86.70% Short Float9.94% Perf Quarter32.57%
Sales26.10M P/S104.08 EPS this Y-428.30% Inst Trans11.45% Short Ratio18.85 Perf Half Y35.55%
Book/sh5.32 P/B4.87 EPS next Y-8.10% ROA-34.60% Target Price29.73 Perf Year28.24%
Cash/sh5.61 P/C4.63 EPS next 5Y- ROE-46.50% 52W Range12.39 - 30.41 Perf YTD48.85%
Dividend- P/FCF- EPS past 5Y- ROI-53.90% 52W High-14.73% Beta-
Dividend %- Quick Ratio12.70 Sales past 5Y- Gross Margin- 52W Low109.28% ATR1.46
Employees268 Current Ratio12.70 Sales Q/Q-14.30% Oper. Margin- RSI (14)52.55 Volatility4.73% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-35.00% Profit Margin- Rel Volume0.33 Prev Close26.82
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume515.86K Price25.93
Recom1.90 SMA202.05% SMA502.96% SMA20027.16% Volume168,728 Change-3.32%
Mar-13-20Upgrade Evercore ISI In-line → Outperform $20
Feb-28-20Upgrade Wedbush Neutral → Outperform $24
Feb-24-20Initiated Jefferies Buy $35
Feb-19-20Initiated Stifel Hold $26
Jan-27-20Upgrade Goldman Neutral → Buy $20 → $37
Sep-26-19Initiated Wedbush Neutral $19
Sep-13-19Initiated Nomura Buy
Aug-09-19Initiated BTIG Research Buy $30
Jun-26-19Initiated H.C. Wainwright Buy $28
Nov-15-18Initiated Cantor Fitzgerald Overweight $25
Nov-12-18Initiated Janney Buy
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Jan-02-18Initiated Morgan Stanley Overweight
Jan-02-18Initiated JP Morgan Overweight $24
Jan-02-18Initiated Goldman Neutral $19
Jan-02-18Initiated Evercore ISI Outperform $23
Jul-07-20 08:00AM  
Jun-28-20 07:06PM  
Jun-10-20 02:03PM  
02:51AM  
Jun-09-20 04:30PM  
May-28-20 11:21AM  
08:00AM  
May-27-20 04:30PM  
May-21-20 12:00PM  
May-10-20 09:18AM  
May-07-20 08:20PM  
04:30PM  
May-06-20 12:30PM  
Apr-15-20 02:49PM  
Apr-09-20 06:08PM  
Apr-02-20 04:30PM  
Feb-29-20 08:47AM  
Feb-27-20 05:55PM  
04:30PM  
Feb-17-20 10:06AM  
Feb-14-20 03:00PM  
12:00PM  
Feb-07-20 11:30AM  
Feb-03-20 11:11AM  
Jan-31-20 08:42PM  
03:02PM  
09:52AM  
Jan-30-20 11:10AM  
10:54AM  
10:15AM  
Jan-29-20 11:11AM  
10:06AM  
Jan-28-20 08:58PM  
11:14AM  
Jan-27-20 04:10PM  
Jan-23-20 09:34AM  
Jan-22-20 10:00AM  
Jan-16-20 09:52AM  
Jan-15-20 09:36AM  
06:11AM  
Jan-14-20 10:03AM  
09:00AM  
Dec-31-19 11:01AM  
Dec-19-19 08:00AM  
Dec-17-19 04:06PM  
Dec-03-19 08:58AM  
Nov-06-19 07:25PM  
04:30PM  
Oct-27-19 11:08AM  
Sep-04-19 09:00AM  
Aug-06-19 08:05PM  
04:30PM  
Aug-05-19 09:00AM  
Aug-01-19 10:33AM  
Jul-04-19 06:03AM  
Jun-29-19 06:27PM  
Jun-12-19 10:30AM  
Jun-11-19 09:00AM  
May-08-19 08:05PM  
04:30PM  
May-03-19 10:30AM  
May-01-19 05:43PM  
Apr-30-19 02:52PM  
Apr-15-19 03:00PM  
Apr-10-19 10:03AM  
Apr-02-19 02:46PM  
Mar-14-19 02:42PM  
Mar-12-19 10:35AM  
09:00AM  
Feb-19-19 07:55AM  
Feb-15-19 09:00AM  
Jan-30-19 09:49AM  
Jan-08-19 09:00AM  
Dec-10-18 09:00AM  
Dec-08-18 10:02AM  
Nov-26-18 10:04AM  
Nov-20-18 08:29AM  
Nov-19-18 04:30PM  
Nov-08-18 05:34PM  
04:30PM  
Nov-01-18 07:30AM  
02:34AM  
02:00AM  
Oct-23-18 08:40AM  
Oct-19-18 08:03AM  
Oct-03-18 09:00AM  
09:00AM  
Sep-24-18 03:34PM  
Aug-09-18 04:30PM  
Aug-01-18 04:30PM  
Jul-23-18 03:05PM  
May-30-18 04:05PM  
May-21-18 08:52AM  
May-18-18 07:07PM  
May-11-18 08:00AM  
Apr-05-18 08:53AM  
Mar-20-18 11:12AM  
10:48AM  
Mar-19-18 08:00AM  
Feb-08-18 09:00AM  
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRATTON DOUGLAS K10% OwnerJun 30Sale24.0145,3451,088,601448,035Jun 30 07:17 PM
BRATTON DOUGLAS K10% OwnerJun 29Sale24.0182,5781,982,373493,380Jun 30 07:17 PM
BRATTON DOUGLAS K10% OwnerJun 26Sale23.94122,0772,922,078575,958Jun 30 07:17 PM
BRATTON DOUGLAS K10% OwnerJun 23Sale25.7720,024515,969698,035Jun 23 05:41 PM
BRATTON DOUGLAS K10% OwnerJun 22Sale24.7890,0562,231,902718,059Jun 23 05:41 PM
BRATTON DOUGLAS K10% OwnerJun 19Sale24.54144,9203,556,503808,115Jun 23 05:41 PM
Tessier-Lavigne MarcDirectorJun 16Sale26.10400,00010,440,0002,739,043Jun 18 09:41 PM
BRATTON DOUGLAS K10% OwnerJun 05Sale25.751,922,85549,513,51613,644,881Jun 09 04:10 PM
Krognes Steve E.CFO and TreasurerMar 30Sale19.481,42827,8171,006,488Apr 01 06:19 PM
Schuth Alexander O.COO and SecretaryMar 30Sale19.491,42727,81228,662Apr 01 06:19 PM
Watts Ryan J.President and CEOMar 30Sale19.484,80793,64022,013Apr 01 06:17 PM
Ho CaroleChief Medical OfficerMar 30Sale19.481,42827,8172,822Apr 01 06:18 PM
BRATTON DOUGLAS K10% OwnerFeb 26Sale20.253,894,76478,868,97115,567,736Feb 28 04:25 PM
Ho CaroleChief Medical OfficerDec 23Sale20.013,46469,3150Dec 23 07:35 PM
Ho CaroleChief Medical OfficerDec 20Sale20.0086017,2003,464Dec 23 07:35 PM
Ho CaroleChief Medical OfficerDec 19Sale20.002,56651,3204,324Dec 23 07:35 PM
Schuth Alexander O.COO and SecretaryDec 04Option Exercise5.283,12116,47928,960Dec 05 05:16 PM
Watts Ryan J.President and CEODec 04Sale18.0018,755337,5902,429,304Dec 05 04:29 PM
Schuth Alexander O.COO and SecretaryDec 04Sale18.002,65647,808580,710Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryDec 04Sale18.003,12156,17825,839Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryDec 03Option Exercise5.287113,75426,550Dec 05 05:16 PM
Watts Ryan J.President and CEODec 03Sale18.022,51345,2842,448,059Dec 05 04:29 PM
Schuth Alexander O.COO and SecretaryDec 03Sale18.011,01218,226583,366Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryDec 03Sale18.0171112,80525,839Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryNov 26Sale18.022294,127584,378Nov 26 05:08 PM
Schuth Alexander O.COO and SecretaryNov 25Sale18.0214,125254,533584,607Nov 26 05:08 PM
Watts Ryan J.President and CEONov 25Sale18.0242,185760,1742,450,572Nov 26 06:17 PM
Watts Ryan J.President and CEONov 22Sale18.001,30023,4002,492,757Nov 26 06:17 PM
Schuth Alexander O.COO and SecretaryNov 22Sale18.0064611,628598,732Nov 26 05:08 PM